Clinical Research Focus. 40th Edition

FDA to Phase Out Animal Testing for Monoclonal Antibody Drugs

The FDA announced plans to phase out animal testing requirements for monoclonal antibody therapies, encouraging the use of New Approach Methodologies (NAMs) like AI models and human cell lines. A pilot program will test these alternatives, aiming to improve drug safety, cut costs, and speed up patient access.

Learn more

Hatch-Waxman: The Underrated Power Tool in the Biotech Playbook

In the world of biotech, where innovation meets regulation, every edge matters. And yet, one of the most potent tools available to biopharma companies, especially smaller, agile players, is often misunderstood, underutilized, or flat-out ignored. We are talking about the Hatch-Waxman Act, a foundational FDA law that few biotech teams truly leverage to its full potential.

Learn more

FDA vs. EMA: Navigating Divergent Regulatory Expectations for Cell and Gene Therapies. What Biopharma Companies Need to Know

The regulatory landscape for cell and gene therapies (CGTs) remains highly fragmented, with significant differences between the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These differences affect clinical trial design, approval timelines, data requirements, and post-marketing surveillance, creating challenges for biopharma companies seeking regulatory approval in both markets.

Learn more

Non-Surgical Treatments for Low Back Pain: A Systematic Review

A comprehensive analysis published in BMJ Evidence-Based Medicine reveals a stark reality: only about 1 in 10 common non-surgical and non-invasive treatments for lower back pain demonstrate effectiveness, with pain relief barely surpassing placebo effects. Given that approximately 80% of adults will experience back pain during their lifetime, these findings underscore the urgent need for more efficacious therapeutic strategies in this prevalent and debilitating condition.

Learn more

AI Screening for Opioid Use Disorder Reduces Hospital Readmissions​

A recent NIH-supported clinical trial demonstrated that an AI-driven screening tool effectively identifies hospitalized adults at risk for opioid use disorder (OUD) and recommends referrals to addiction specialists. The AI system matched healthcare providers in initiating consultations and monitoring withdrawal. Notably, patients screened by AI had a 47% lower chance of 30-day hospital readmission, leading to nearly $109,000 in healthcare savings during the study. These findings suggest AI can enhance addiction care and hospital efficiency. ​

Learn more

Engaging Early with EMA Scientific Advice: A Strategic Advantage for Sponsors

For companies planning clinical trials or pursuing marketing authorization in the European Union (EU), early engagement with the European Medicines Agency (EMA) through its Scientific Advice procedure can be a game-changing strategy. This is especially true for small to mid-sized developers and non-EU sponsors who may be less familiar with the European regulatory environment.

Learn more

Trump Administration Freezes Over $2.2 Billion in Harvard Funding

The Trump administration froze over $2.2 billion in federal funding to Harvard University after it refused to meet demands for policy changes. According to Harvard, the lost funds risk halting research on cancer, heart disease, infectious diseases, and more. University leaders warned that such government interference could endanger public health and national security.

Learn more

CT Scans and Future Cancer Risk: Time to Recalibrate How We Use Imaging

A major new study in JAMA Internal Medicine estimates that computed tomography (CT) scans performed in 2023 could lead to over 100,000 future cancer cases in the US—an alarming projection that may place CT as the source of up to 5% of all new cancer diagnoses annually, if current practices continue

Learn more

Enhertu Plus Pertuzumab Shows Strong PFS Benefit in HER2-Positive Breast Cancer

In the Phase III DESTINY-Breast09 trial, Enhertu (Daiichi Sankyo and AstraZeneca), when combined with pertuzumab, delivered a significant improvement in progression-free survival over standard first-line therapy in patients with HER2-positive metastatic breast cancer. The results signal a potential shift in the treatment landscape, positioning the combination as a strong contender for a new standard of care.

Learn more